Impact of the highly active antiretroviral therapy era on the epidemiology of primary HIV-associated thrombocytopenia

Primary HIV-associated thrombocytopenia (PHAT) typically improves with highly active antiretroviral therapy (HAART); however, cases continue to occur. Data comparing the epidemiology of PHAT between the pre-HAART and HAART eras are limited. We retrospectively examined the incidence of PHAT over 28 y...

Full description

Saved in:
Bibliographic Details
Published in:BMC research notes 2015-10, Vol.8 (1), p.595-595, Article 595
Main Authors: O'Bryan, Thomas A, Okulicz, Jason F, Bradley, William P, Ganesan, Anuradha, Wang, Xun, Agan, Brian K
Format: Article
Language:English
Subjects:
Analysis
Antiretroviral Therapy, Highly Active
Antiviral agents
Care and treatment
Development and progression
Epidemiology
Female
Genetic aspects
Health aspects
Highly active antiretroviral therapy
HIV (Viruses)
HIV Infections - complications
Humans
Male
Risk factors
Short Report
Thrombocytopenia
Thrombocytopenia - drug therapy
Thrombocytopenia - epidemiology
Thrombocytopenia - etiology
Virus diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary HIV-associated thrombocytopenia (PHAT) typically improves with highly active antiretroviral therapy (HAART); however, cases continue to occur. Data comparing the epidemiology of PHAT between the pre-HAART and HAART eras are limited. We retrospectively examined the incidence of PHAT over 28 years in the US Military HIV Natural History Study (NHS) from 1986 to 2013. Subjects had a nadir platelet count
ISSN:1756-0500
1756-0500
DOI:10.1186/s13104-015-1548-3